BioLuminate, Inc. is a biotechnology and medical device company developing a diagnostic device for the early diagnosis of breast cancer using technology originally invented by NASA. Today, 85% (1,115,000 biopsies) of all breast biopsies are found negative each year in the US. The BioLuminate system will dramatically reduce this number of unnecessary biopsies, which costs our health care system over $2.3 billion annually. It will detect a significant portion of the breast cancers that are missed each year by the current marginal screening procedures. It is also expected to greatly improve breast cancer screening effectiveness, especially in younger women, where mammograms are less effective because of denser breast tissue. In addition, it will serve as an aiming device and deliver therapy, for core needle biopsies; cancer markers; laser heat; cryogenics; drugs, and radioactive seeds.
